Prothena Co. PLC (NASDAQ:PRTA) has earned a consensus rating of “Buy” from the thirteen ratings firms that are presently covering the firm, MarketBeat reports. Two research analysts have rated the stock with a sell rating, two have given a hold rating and nine have assigned a buy rating to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $74.75.
A number of analysts have recently commented on the company. BidaskClub raised Prothena from a “strong sell” rating to a “sell” rating in a research note on Thursday, January 11th. ValuEngine downgraded Prothena from a “sell” rating to a “strong sell” rating in a research note on Wednesday, February 7th. Zacks Investment Research raised Prothena from a “sell” rating to a “hold” rating in a research note on Monday, February 19th. Oppenheimer set a $70.00 price objective on Prothena and gave the stock a “buy” rating in a research note on Thursday, February 15th. Finally, Wedbush downgraded Prothena from an “outperform” rating to a “neutral” rating and dropped their price objective for the stock from $75.00 to $55.00 in a research note on Monday, November 20th.
Shares of Prothena (NASDAQ PRTA) traded down $0.56 during mid-day trading on Friday, reaching $34.03. The company’s stock had a trading volume of 15,904 shares, compared to its average volume of 480,354. Prothena has a one year low of $27.19 and a one year high of $70.00.
Prothena (NASDAQ:PRTA) last posted its quarterly earnings data on Wednesday, February 14th. The biotechnology company reported ($1.24) EPS for the quarter, topping the Zacks’ consensus estimate of ($1.48) by $0.24. Prothena had a negative return on equity of 33.37% and a negative net margin of 556.84%. The company had revenue of $0.23 million for the quarter, compared to the consensus estimate of $0.27 million. During the same quarter in the previous year, the business earned ($1.41) EPS. The company’s quarterly revenue was up 33.9% compared to the same quarter last year. sell-side analysts expect that Prothena will post -5.87 earnings per share for the current fiscal year.
Institutional investors have recently made changes to their positions in the company. Strs Ohio raised its position in shares of Prothena by 69.2% during the third quarter. Strs Ohio now owns 2,200 shares of the biotechnology company’s stock worth $142,000 after purchasing an additional 900 shares during the period. Fieldpoint Private Securities LLC acquired a new stake in shares of Prothena during the third quarter worth $162,000. Teacher Retirement System of Texas acquired a new stake in shares of Prothena during the third quarter worth $206,000. HL Financial Services LLC acquired a new stake in shares of Prothena during the third quarter worth $208,000. Finally, First Trust Advisors LP acquired a new stake in shares of Prothena during the third quarter worth $212,000.
COPYRIGHT VIOLATION NOTICE: This piece was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another site, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2018/03/21/brokerages-set-prothena-co-plc-prta-price-target-at-74-75.html.
Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter.